首页> 美国卫生研究院文献>Rheumatology Advances in Practice >Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?

【2h】

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?

机译：Covid-19是否导致患有生物DMARD或靶向合成DMARD的炎症性风湿性疾病患者的住院或死亡风险增加？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

•Poor outcomes from severe acute respiratory syndrome coronavirus-2 are not common for patients with inflammatory rheumatic diseases taking advanced therapies.

机译：•严重急性呼吸综合征Coronavirus-2的良差结果对于患有先进疗法的炎症性风湿性疾病的患者对患者并不常见。

著录项

期刊名称 Rheumatology Advances in Practice
作者
May Lwin; Christopher Holroyd; Dinny Wallis; Brian Davidson; Lyndsey Goulston; Hans de Graaf; Christopher J Edwards;
展开▼
作者单位

展开▼
年(卷),期 2020(4),2
年度 2020
页码 rkaa061
总页数 2
原文格式 PDF
正文语种
中图分类免疫性疾病;
关键词
入库时间 2022-08-21 12:16:56

相似文献

外文文献
中文文献
专利

1. A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases [J] . B.-Y. Nordv?￥g, C. Kaufmann, E. Lie, Clinical and experimental rheumatology . 2005,第5期

机译：挪威DMARD登记册：炎性风湿病患者的DMARD和生物制剂处方
2. A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases [J] . B.-Y. Nordv?￥g, C. Kaufmann, E. Lie, Clinical and experimental rheumatology . 2005,第5期

机译：挪威DMARD登记册：炎性风湿病患者的DMARD和生物制剂处方
3. High resistin levels increase the risk for erosive disease in patients with early rheumatoid arthritis (RA) treated with a combination of disease-modifying anti-rheumatic drugs (DMARDs): the NEO-RACo study [J] . Vuolteenaho K., Kautiainen H., Tuure L., Scandinavian journal of rheumatology . 2015,第6期

机译：NEO-RACo研究表明，高抵抗素水平增加了早期风湿性关节炎（RA）患者的抗风湿药（DMARDs）联合治疗的侵蚀性疾病风险
4. Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases [C] . J.-F. COLOMBEL, M. TORUNE Falk Symposium . 2007

机译：炎症性肠病患者的发病率增加了与免疫调节治疗有关的发病危险
5. Targeting cyclophilin-CD147 interaction as an approach to treat inflammatory diseases [D] . Gill, Mandeep Kaur 2009

机译：靶向亲环蛋白-CD147相互作用作为一种治疗炎症性疾病的方法
6. ‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’ [O] . Susan M Goodman MD, Michael D George MD MSCE 2020

机译：我们应该在炎症性风湿病患者的手术前停止或继续常规合成（包括糖皮质激素）和靶向DMARD吗？
7. Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs? [O] . May Lwin, Christopher Holroyd, Dinny Wallis, 2020

机译：Covid-19是否导致患有生物DMARD或靶向合成DMARD的炎症性风湿性疾病患者的住院或死亡风险增加？

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?

摘要

著录项

相似文献

相关主题

期刊订阅